Decheng Capital’s Adicet Bio ACET Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
– Sell
-12,513
Closed -$274K – 25
2023
Q3
$274K Sell
12,513
-19,091
-60% -$674K 0.09% 26
2023
Q2
$1.23M Sell
31,604
-4,646
-13% -$410K 0.39% 22
2023
Q1
$3.34M Hold
36,250
– – 1.35% 16
2022
Q4
$5.19M Hold
36,250
– – 1.94% 15
2022
Q3
$8.25M Hold
36,250
– – 2.99% 11
2022
Q2
$8.47M Hold
36,250
– – 3.21% 9
2022
Q1
$11.6M Hold
36,250
– – 3.55% 9

Other funds holding ACET

Decheng Capital's ACET Position: Q4 2023 in Review

Decheng Capital sold out of Adicet Bio (ACET) in Q4 2023, closing a stake of 12,513 shares — an estimated $274K sold.

Decheng Capital first reported a position in ACET in Q1 2022 and held it in 7 quarters. The position peaked at $11.6M in Q1 2022. 76 funds tracked by Wall St. Rank hold ACET as of Q4 2023.

  • Decheng Capital reported no remaining Adicet Bio position as of Q4 2023 after selling out during the quarter.
  • Decheng Capital sold 12,513 Adicet Bio shares in Q4 2023, an estimated $274K.
  • Decheng Capital first reported a position in Adicet Bio in Q1 2022 and held it in 7 quarters.
  • Decheng Capital's Adicet Bio position peaked at $11.6M in Q1 2022.
  • 76 funds tracked by Wall St. Rank held Adicet Bio as of Q4 2023.

Based on Decheng Capital's 13F filing for Q4 2023, filed 12 Feb 2024.